Phenobarbital-induced CD4+ upregulation predicts seizure reduction in epilepsy
https://doi.org/10.58708/2074-2088.2025-3(35)-42-48
Abstract
In this prospective pilot cohort study (November–December 2024, Kadhimiya Hospital, Iraq), 40 patients (26 men, 14 women; ages 25-50) with confirmed epilepsy received oral phenobarbital (10 mg/mL, 12 weeks). CD4+ concentrations (ng/mL via ELISA after MACS isolation) and seizure frequency were assessed pre- and post-treatment. Paired t-tests, ANOVA, and Pearson correlations were used (p<0.05 significant; effect sizes reported). CD4+ levels increased from 15,2 ± 4,3 ng/mL to 22,8 ± 5,6 ng/mL (p<0,001; Cohen’s d=1,35; 95% CI for difference: 5,9-9,3). Seizure frequency decreased by 78% (8,9 ± 3,79 to 1,93 ± 1,53; p<0,001; Cohen’s d=2,01). Posttreatment CD4+ inversely correlated with seizure frequency (r=-0,62, p<0,001; 95% CI: -0,78 to -0,40) and positively with clinical response (r=0,85, p<0,001; 95% CI: 0,75 to 0,91). Patients with CD4+ >22 ng/mL had 83% response rate versus 42% below. Females showed higher response rates (80% versus 73% males) despite lower CD4+ folds. Thus, PB is associated with CD4+ upregulation and seizure reduction, suggesting potential as a biomarker of therapeutic response.
About the Authors
M. Ghaith
Belarusian State University, ISEI BSU; Al-Kadhimiya Teaching Hospital
Iraq
Iraq
Minsk;
Alkadhmiya
A. G. Sysa
Belarusian State University, ISEI BSU
Belarus
Belarus
Minsk
E. P. Zhyvitskaya
Belarusian State University, ISEI BSU
Belarus
Belarus
Minsk
References
1. World Health Organization. Epilepsy. WHO Fact Sheet. Electronic source. Mode of access: https://www.who.int/news-room/fact-sheets/detail/epilepsy. Date of access: June 15, 2025.
2. Newton CR, Garcia HH. Epilepsy in poor regions of the world. Lancet. 2012, no. 380(9848), pp. 1193-1201. doi:10.1016/S0140-6736(12)61381-6.
3. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989, no. 25(3), pp. 213-220. doi:10.1002/ana.410250302.
4. Marchi N, Granata T, Janigro D. Inflammatory pathways of seizure disorders. Trends Neurosci. 2014, no. 37(2), pp. 55-65. doi:10.1016/j.tins.2013.11.002.
5. Andrzejczak D. Padaczka a cytokiny prozapalne. Immunomodulujące właściwości leków przeciwpadaczkowych [Epilepsy and pro-inflammatory cytokines. Immunomodulating properties of antiepileptic drugs. Neurol Neurochir Pol. 2011, no. 45(3), pp. 275-285. doi:10.1016/s0028-3843(14)60080-3.
6. Mu L, Rong Y, Xin YJ, Zhang H, Xu Z. Research Progress on Th17/Treg Cell Imbalance in Epileptic Seizures. J Inflamm Res. 2025, no. 18, pp. 7769-7779. https://doi.org/10.2147/JIR.S524814.
7. Wang XL, Shen GX, Sun B, Su N. Studies on lymphocyte subpopulations and NK cell activities in epileptic patients. J Tongji Med Univ. 1989, no. 9(1), pp. 25-28. doi:10.1007/BF02933740.
8. Roseti C, van Vliet EA, Cifelli P, et al. GABAA currents are decreased by IL-1β in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis. Neurobiol Dis. 2015, no. 82, pp. 311-320. doi:10.1016/j.nbd.2015.07.003.
9. Vezzani A. Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr. 2014, no. 14(1 Suppl), pp. 3-7. doi:10.5698/1535-7511-14.s2.3.
10. Reddy DS, Abeygunaratne HN. Experimental and Clinical Biomarkers for Progressive Evaluation of Neuropathology and Therapeutic Interventions for Acute and Chronic Neurological Disorders. Int J Mol Sci. 2022, no. 23(19), pp. 11734. doi:10.3390/ijms231911734.
11. Hendrix E, Vande Vyver M, Holt M, Smolders I. Regulatory T cells as a possible new target in epilepsy? Epilepsia. 2024, no. 65, pp. 2227-2237. https://doi.org/10.1111/epi.18038.
12. Beghi E, Shorvon S. Antiepileptic drugs and the immune system. Epilepsia. 2011, no. 52 Suppl 3, pp. 40-44. doi:10.1111/j.1528-1167.2011.03035.x
13. Xu C, Wyman AR, Alaamery MA, et al. Antiinflammatory effects of novel barbituric acid derivatives in T lymphocytes. Int Immunopharmacol. 2016, no. 38, pp. 223-232. doi:10.1016/j.intimp.2016.06.004.
14. Dhir A. Pentylenetetrazol (PTZ) kindling model of epilepsy. Curr Protoc Neurosci. 2012, Chapter 9, Unit 9.37. doi:10.1002/0471142301.ns0937s58.
15. Wilkinson NM, Chen HC, Lechner MG, Su MA. Sex Differences in Immunity. Annu Rev Immunol. 2022, no. 40, pp. 75-94. doi:10.1146/annurev-immunol-101320-125133.
Review
For citations:
Ghaith M., Sysa A.G., Zhyvitskaya E.P. Phenobarbital-induced CD4+ upregulation predicts seizure reduction in epilepsy. Medical and Biological Problems of Life Activity. 2025;(3):42-48. https://doi.org/10.58708/2074-2088.2025-3(35)-42-48
Views:
1
Email this article 